ImmunityBio Inc (IBRX)

IBRX's stock fell 6.06% related to the investigation claims against the company. The investigation focuses on whether IBRX issued false and/or misleading statements and/or failed to disclose information pertinent to investors. ImmunityBio announced on May 11, 2023, that it "has received a complete response letter from the U.S. Food and Drug Administration ("FDA") on May 9, 2023 regarding its Biologics License Application ("BLA") for its product candidate, Anktiva™ (N-803) in combination with Bacillus Calmette-Guérin ("BCG"). The letter indicates that the FDA has determined that it cannot approve the BLA in its present form, and the FDA has made recommendations to address the issues raised."

https://www.accesswire.com/viewarticle.aspx?id=756192&lang=en

ImmunityBio’s stock price has fallen after receiving a response from the U.S. Food and Drug Administration (FDA). The FDA has rejected ImmunityBio’s application for Anktiva as a bladder cancer treatment.

https://investorplace.com/2023/05/why-is-immunitybio-ibrx-stock-down-54-today/